FDA Approves TZIELD — Provention Bio, Inc.

The FDA granted accelerated approval to Provention Bio’s TEPLIZUMAB-MZWV (TZIELD), a novel immunotherapy for type 1 diabetes, significantly bolstering the company’s product pipeline and strengthening its competitive position within the automated insulin delivery sector. This pivotal regulatory milestone facilitates immediate access to a new treatment modality while opening opportunities to capture a substantial share of the rapidly expanding beta-cell preservation market.